KRAS and gastric cancer: However, in contrast to the co-activation of AKT and STAT3 signaling in PIK3R1 loss ovarian cancer cells, the molecular rationale underlying the synergism in the KRAS mutant gastric cancer cells is the activation of STAT3 upon inhibition of PI3K signaling.